
Annual report 2024
added 10-25-2025
Kamada Ltd. Net Debt 2011-2025 | KMDA
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Kamada Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | -70.2 M | -38.4 M | -17.4 M | -11.3 M | -8.19 M | -4.86 M | -7.1 M | -42.9 M | 7.25 M | -1.94 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.25 M | -70.2 M | -19.5 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Graybug Vision
GRAY
|
-33.4 M | $ 0.44 | -11.23 % | $ 9.65 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | $ 11.3 | -10.17 % | $ 12.2 K | - | |
|
Galera Therapeutics
GRTX
|
-19.8 M | $ 0.14 | -32.59 % | $ 7.61 M | ||
|
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
1.09 M | $ 4.37 | -1.58 % | $ 28.1 M | ||
|
Axon Enterprise
AXON
|
-404 M | $ 755.0 | 0.8 % | $ 57.2 B | ||
|
Caladrius Biosciences
CLBS
|
-22.3 M | $ 0.43 | -16.75 % | $ 25.8 M | ||
|
Sorrento Therapeutics
SRNE
|
85.5 M | $ 0.27 | -29.58 % | $ 126 M | ||
|
BeiGene, Ltd.
BGNE
|
-2.44 B | $ 184.71 | 0.49 % | $ 251 B | ||
|
ContraFect Corporation
CFRX
|
-6.03 M | $ 1.47 | -5.16 % | $ 5.39 M | ||
|
Orchard Therapeutics plc
ORTX
|
-39 M | $ 4.93 | 1.02 % | $ 90.8 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | $ 0.29 | -18.52 % | $ 27.3 M | ||
|
Advaxis
ADXS
|
3.42 M | $ 0.31 | -9.65 % | $ 45.9 M | ||
|
Heat Biologics, Inc.
HTBX
|
-9.08 M | $ 3.93 | -5.76 % | $ 99.8 M | ||
|
La Jolla Pharmaceutical Company
LJPC
|
-46.4 M | $ 6.2 | - | $ 154 M | ||
|
Zymeworks
ZYME
|
-200 M | $ 6.42 | - | $ 404 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | $ 5.72 | 5.93 % | $ 314 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
-12.1 M | $ 10.5 | - | $ 231 M | ||
|
Kadmon Holdings, Inc.
KDMN
|
-71.4 M | $ 9.5 | - | $ 1.7 B | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | $ 2.58 | -4.8 % | $ 255 M | ||
|
Mesoblast Limited
MESO
|
-50.2 M | $ 16.73 | 0.12 % | $ 10.9 B | ||
|
Zosano Pharma Corporation
ZSAN
|
-6.36 M | $ 0.56 | 7.23 % | $ 2.72 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | $ 0.5 | - | $ 7.46 M | ||
|
Kiromic BioPharma
KRBP
|
-224 K | $ 3.15 | 6.61 % | $ 3.08 M | ||
|
Acceleron Pharma Inc.
XLRN
|
-654 M | $ 179.68 | - | $ 10.9 B | ||
|
Moderna
MRNA
|
-1.87 B | $ 25.35 | -4.91 % | $ 9.73 B | ||
|
Albireo Pharma
ALBO
|
-239 M | $ 44.15 | -0.23 % | $ 916 M | ||
|
Merus N.V.
MRUS
|
-283 M | $ 94.9 | 0.32 % | $ 6.09 B | ||
|
Stealth BioTherapeutics Corp
MITO
|
-14.8 M | $ 0.32 | - | $ 23.9 M | ||
|
Trillium Therapeutics Inc.
TRIL
|
-247 M | $ 18.44 | - | $ 1.94 B | ||
|
Kaleido Biosciences
KLDO
|
-25.2 M | $ 0.29 | -3.69 % | $ 12.4 M | ||
|
Entasis Therapeutics Holdings
ETTX
|
-55.1 M | $ 2.19 | - | $ 105 M | ||
|
Humanigen
HGEN
|
-45 M | $ 0.04 | -81.12 % | $ 4.28 M | ||
|
Aptinyx
APTX
|
-33.8 M | $ 0.06 | -39.0 % | $ 4.57 M | ||
|
Tyme Technologies
TYME
|
-107 M | $ 0.31 | 8.07 % | $ 54 M | ||
|
Forward Pharma A/S
FWP
|
-57.9 M | $ 2.64 | -0.75 % | $ 18.7 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | $ 0.39 | - | $ 26.5 M | ||
|
Celyad Oncology SA
CYAD
|
-38.1 M | $ 0.47 | - | $ 12.5 M | ||
|
Nektar Therapeutics
NKTR
|
82.5 M | $ 60.92 | -2.64 % | $ 11.6 B | ||
|
Brickell Biotech
BBI
|
-29.7 M | $ 2.11 | -5.38 % | $ 6.06 M | ||
|
Genocea Biosciences
GNCA
|
-30.7 M | $ 0.05 | -15.0 % | $ 3.04 M | ||
|
Codiak BioSciences
CDAK
|
-39.4 M | $ 0.06 | -55.98 % | $ 2.15 M | ||
|
Concert Pharmaceuticals
CNCE
|
-127 M | $ 8.37 | - | $ 401 M | ||
|
AIkido Pharma
AIKI
|
-1.04 M | $ 3.17 | 1.93 % | $ 17.4 M | ||
|
Calithera Biosciences
CALA
|
-56.5 M | $ 0.37 | -10.95 % | $ 876 K | ||
|
Ocular Therapeutix
OCUL
|
-385 M | $ 11.53 | -0.17 % | $ 1.82 B | ||
|
Forma Therapeutics Holdings
FMTX
|
-44.7 M | $ 20.01 | - | $ 958 M | ||
|
Oragenics
OGEN
|
-11.1 M | $ 1.29 | -2.27 % | $ 2.9 M | ||
|
Arena Pharmaceuticals
ARNA
|
-25.4 M | $ 49.55 | -6.81 % | $ 3.04 B | ||
|
Oncolytics Biotech
ONCY
|
-13.7 M | $ 1.22 | 0.83 % | $ 115 M |